EMEA-000828-PIP01-09-M09 - paediatric investigation plan

empagliflozin
PIP Human

Key facts

Invented name
  • Jardiance
  • Jardiance
Active substance
empagliflozin
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/0283/2021
PIP number
EMEA-000828-PIP01-09-M09
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries

Boehringer Ingelheim International GmbH 
E-mail: COMMSPaediatrics@boehringer-ingelheim.com
Tel. +49 (0)6132 77 8271 
 

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance check done
Yes
Compliance procedure number
EMEA-C-000828-PIP01-09-M09
Compliance opinion date
Compliance outcome
Positive

Decision

Share this page